Introduction
Human skin and other nonlymphoid tissues contain several subsets of DCs and macrophages [1, 2] . In addition to LCs of stratified epidermis, the interstitial tissues contain CD1c + myeloid DCs and a minor population of CD141 high myeloid DCs that mirror the CD1c + and CD141 + blood DC populations [3] . CD141 + myeloid DCs are homologous to CD8 + and CD103 + DCs in mice that express XCR1 and have enhanced cross-presentation capacity. XCR1 + DCs have been referred to as "DC1" and the CD1c + myeloid DC as "DC2" in a recently proposed classification of mammalian DCs [2] .
Human LCs are characterized by high expression of langerin, a C-type lectin, and CD1a. Interstitial tissue DCs also express CD1a but at a lower level to that found on LCs [3] [4] [5] [6] [7] [8] [9] . Dermal and lung CD1a + /CD1c + DCs (DC2) have been reported previously to be langerin negative [7, 10] , although langerin expression was reported in the lamina propria of human colon [11] .
The selective expression of pattern recognition receptors, including lectins and TLRs, confers specialized functions to different populations of DCs. Langerin is able to bind viruses and other pathogens, is implicated in antigen processing, and is found within the Birbeck granule of LCs [12] [13] [14] . These observations do not exclude a role for langerin in other DC populations.
In mice, langerin is also expressed by XCR1 + crosspresenting DCs (DC1), expressing CD103 + in the tissues or CD8 + in the lymphoid organs [15] [16] [17] [18] [19] [20] . In humans, however, the DC1 subset of CD141 high XCR1 + myeloid DCs is langerin negative [3] .
In human progenitor cells and monocytes, langerin is induced by a wide range of cytokines in vitro, including GM-CSF, TNF, TGF-b, and BMP-7 [8, [21] [22] [23] [24] . These results suggest that langerin might be expressed by other DCs outside of the LC compartment. In this report, we set out to re-examine the question of langerin expression by human DCs in situ and found evidence of langerin expression by CD1c + myeloid DCs.
MATERIALS AND METHODS

Samples and patient data
Blood, skin, and surplus biopsy material was obtained from healthy human volunteers and hematopoietic transplant patients under ethical approval from the Newcastle and North Tyneside Research Ethics Committee 1. Skin, tissues, and blood were processed as described previously [3] .
Flow cytometry and cell sorting 
Langerin Induction on blood DCs
Unfractionated PBMCs (2 3 10 6 ) were incubated in 1 ml RPMI with 10% FCS for 18 h, with or without TGF-b (100 ng/ml). In experiments with sorted cells, 10,000 cells were cultured in 100 ml. Cells were stained in the same Eppendorfs for surface expression of langerin and analyzed by flow cytometry initially and after 18 h. Recombinant human BMPR-IA/ALK-3 Fc chimera was obtained from R&D Systems (315-BR-100) and used at 2 mg/ml. ). This consistently demonstrated langerin + dermal DCs (Fig. 1B) . Additional antigens CD13, CD31, CD11c, and CD11b were able to dissociate LCs from langerin + DCs (Fig. 1B) . Comparison of all surface antigens analyzed suggested that langerin + DCs were closely related to CD1a + dermal DCs and distinct from LCs. All subsets expressed CD1c (Fig. 1C) .
The phenotype of langerin + DCs was explored further with qPCR. First, comparison with the signature of CD141 high XCR1 + DCs showed that dermal langerin + DCs did not express the characteristic markers of cross-presenting DCs: XCR1, NECL2, and CLEC9 ( Fig. 2A) . Growth factor receptor expression profiles showed that langerin + DCs had a high Flt-3/low M-CSFR signature in common with CD1a + dermal DCs and distinct from LCs and CD14 + monocyte-derived cells (Fig. 2B) . The TLR profile of langerin + DCs was similar to that of CD1a + dermal DCs, although all myeloid cells expressed a similar array of receptors (Fig. 2C) .
Langerin + CD1c + DCs were also detectable in tissues normally devoid of LCs, including the lung, liver, and tonsil. There was variable expression of CD1a; higher levels were detected in the lung than liver or tonsil (Fig. 3A) .
We examined skin and lung with matched draining LNs to determine whether the phenotype of langerin + DCs in draining LNs was concordant with the tissues (Fig. 3B) . Matched populations of langerin + DCs and LCs, separable by CD11c and CD1a expression, were observed in skin and axillary LNs. In the lung and bronchial LNs, only langerin + DCs but no LCs were found. The langerin + DCs from both tissue and corresponding LN had a similar phenotype (Fig. 3B) .
Immunofluorescence (Fig. 4A) . With the use of CD11c expression to separate langerin + DCs from LCs, it was possible to detect occasional langerin + DCs in situ in the apical dermis. These also showed a similar diffuse pattern of langerin staining in contrast to the bright langerin expression of migrating LCs (Fig. 4B) . Several attempts were made to detect Birbeck granules in sorted populations of langerin + DCs, but none was found (not shown).
The homeostasis of langerin + dermal DCs is distinct from that of LCs
Maturing LCs down-regulate langerin expression and may acquire the characteristics of myeloid DCs. To verify that langerin + dermal DCs were not derived from LCs, we examined 2 in vivo models of human DC homeostasis: HSCT and human DC deficiency as a result of GATA2 mutation. In patients receiving HSCT, LCs remain predominantly recipient in origin for the first 28 d post-transplant, whereas donor-derived cells replace the blood and interstitial DC compartments [9, 25] . Langerin + DCs and LCs were isolated from skin biopsies at day 28 of sex-mismatched transplants and probed with X-Y FISH. This indicated that langerin + DCs were replaced rapidly by donor-derived cells (80-90%) in parallel with CD1a + dermal DCs, blood monocytes, and blood DCs. All of these populations engrafted with much more rapid kinetics than LCs, which were 10-20% donor at the same time-point. These results indicate that langerin + DCs are unlikely to be derived from maturing epidermal LCs crossing the dermis, as the latter were mostly recipient at the time of analysis (Fig. 5A) .
Patients with DC deficiency as a result of GATA2 mutations lack interstitial DC populations but maintain epidermal LCs [26, 27] . Closer analysis of these patients revealed that langerin + DCs are also missing in parallel with CD1a + dermal DCs. In contrast, the persistence of LCs, including the small afferent population crossing the dermis, further supports the conclusion that langerin + dermal DCs are unlikely to be derived from LCs (Fig. 5B) .
Induction of langerin expression on CD1c + blood myeloid DCs
Having observed langerin + DCs in human tissues, peripheral blood was examined for langerin expression. None was detectable on freshly isolated cells, but langerin was induced at a low level in serum-containing medium and by TGF-b after 18 h of culture of unfractionated PBMC. Flow analysis after 18 h indicated that langerin was expressed selectively by CD1c + myeloid DCs (Fig. 6A) . Addition of TNF-a or GM-CSF, cytokines that are known to derive langerin + DCs, did not further augment the expression of langerin, and langerin induction was not observed on the small number of CD141 + DCs present in these experiments (not shown). Sorted CD1c + myeloid DCs, but not other populations, also expressed langerin after 18 h with serumcontaining medium or with TGF-b (Fig. 6B) . qPCR for langerin showed that freshly isolated CD1c + DCs express a low level of langerin message that was up-regulated in culture with TGF-b. This is in contrast to CD14 + monocytes, which remain negative (Fig. 6C) . It was possible to reduce the level of langerin induction by TGF-b with the use of an ALK-3-Fc chimeric-blocking reagent (Fig. 6D) .
DISCUSSION
These results demonstrate the existence of widely distributed langerin + DCs that have variable expression of CD1a + and are closely related to CD1c + DCs. In the recently proposed classification of mammalian DCs, this subset is related to CD11b + DCs of mice and is known as DC2 [2] . The expression of langerin is low but distinct and is found in sites that do not normally contain LCs, including lymphoid and nonlymphoid tissues. Langerin is not expressed by the CD141 high XCR1 + crosspresenting DC [3] , and conversely, langerin + CD1c + DCs do not express the characteristic markers of cross-presenting DCs. The absence of langerin from human DC1 is an important species difference between mice and humans, contrasting with the consistent expression of langerin by mouse CD8 + /CD103 + DC1 [18] [19] [20] . It should be noted, however, that approximately onethird of langerin + DCs in murine nonlymphoid tissues does not express the DC1 marker CD103, suggesting expression on additional DC populations that may include some DC2 [20] .
In vivo experiments with HSCT recipients and patients with DC deficiency show that langerin + DCs and CD1a + dermal DCs have parallel homeostasis with blood monocytes and DCs and are not derived from LCs. Finally, freshly isolated blood CD1c + DCs contain langerin mRNA and up-regulate langerin surface-antigen expression in response to serum or TGF-b within 18 h. Together, these results indicate that CD1c + myeloid DCs can be induced to express langerin and that in vivo, a fraction of these cells is langerin + , possibly through the action of local environmental factors, such as TGF-b. Langerin has not been detected on tissue DCs of the skin and lung by previous studies [7, 10] , although langerin + DCs were reported in human colon [11] , and there is reference to trace levels of langerin expression in human blood [28, 29] . TGF-b is able to up-regulate expression by CD1c + blood DCs, suggesting that langerin expression in tissues may be induced by epithelial or autocrine TGF-b [30] [31] [32] . The use of an ALK-3-blocking reagent implicates similar TGF-b signaling pathways to those involved in the induction of langerin on progenitor cell populations [24] . One caveat of our experiments is that in vitro preparation of skin by enzymatic digest may have enhanced the level of langerin expression. However, our results also show that langerin + DCs are detectable in situ by immunofluorescence and also found in lung, liver, and LN, tissues that do not require long preparative manipulation.
Expression of langerin by CD34 + progenitors and CD14 monocytes is well described after prolonged in vitro culture [8, [21] [22] [23] [24] [31] [32] [33] . These techniques are usually designed to make LCs, although they may also generate langerin + DCs similar to the phenotype that we describe in vivo. Several investigators have demonstrated Birbeck granules in in vitro-derived LCs. We were unable to find these organelles in primary langerin + DCs. This may have been hampered by effacement of ultrastructural features following cell sorting, although it is notable that langerin + DCs in mice also express less langerin than LCs and to our knowledge, have not been shown to contain Birbeck granules [15] [16] [17] .
The finding that CD1c + DCs can express langerin may have relevance to the pathogenesis of LCH, a rare, low-grade myeloproliferative-inflammatory disorder characterized by an abnormal accumulation of langerin + CD1a + myeloid cells. Comparison of a limited number of surface antigens confirmed that LCH cells are quite different to LCs [32, [34] [35] [36] [37] . The lack of EpCAM, lower CD1a, and expression of CD11b, CD13, and CD33 by LCH cells is also a feature more in keeping with langerin + CD1c + DCs than LCs. A langerin + DC origin for LCH is perhaps more consistent with the widespread distribution of multisystem LCH and absence of Birbeck granules in the liver and gastrointestinal tract [38] . Genetic tracking of mutations causing LCH have identified CD11c
+ myeloid cells, which include CD1c + DCs as potential precursors [39] . Further studies will be required to evaluate the potential links between CD1c + myeloid DCs and this disease.
In summary, these results show that langerin expression is not confined to human LCs in vivo but is expressed at low level by a fraction of nonlymphoid and lymphoid CD1c + DCs and is induced rapidly on blood CD1c + DCs in vitro.
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